NAL Pharma is a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems based on the Company’s captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Drug Delivery System (“DDS”) technologies.
Headquartered in Hong Kong and with operation in the United States, NAL is developing non-infringing, proprietary and improved drug delivery systems that exhibit enhanced patient-compliance, safety, and/or efficacy compared with existing pharmaceutical products, and is also developing specially designed delivery systems to improve conventional dosage forms of new drugs undergoing Phase 2 clinical development that show significant first-pass metabolism side effects, poor solubility, and poor bioavailability.
As the US operation of NAL, Galaxy Bio, Inc. ("GBI") has established a captive R&D Laboratory in Princeton, New Jersey, USA for the development of afore-mentioned NAL's innovative and proprietary DDS products. Combining established product formulation and manufacturing development expertise, NAL has developed a number of non-infringing, proprietary and improved therapeutic products that incorporate patent-expiring drugs. NAL is working with major consumer healthcare companies to extend the life cycle of patent expiring drugs for the Rx-to-OTC switch. NAL is also working with major pharmaceutical companies to improve the formulations of their NCE drugs under development, in an effort to develop the most effective delivery systems based on NAL’s proprietary DDS Technologies.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Room 401, No. 93-103 Wing Lok Street,, Shung Wan,hong Kong 999077,hong Kong
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.nalpharma.com
- Keywords
- Bio-FX Fast-Onset Orally-Dissolving Film (ODF) DDS Technology, Bio-D3 Transdermal Patch DDS Technology, Bio-CR Oral Controlled-Release DDS Technology, Bio-NN Nanoparticle Controlled-Release Injectable DDS Technology, Bio-MM Microsphere Extended-Release “Depot” Injectable DDS Technology.
- HQ
- Shung Wan, Hong Kong
Nal Pharmaceutical Group Limited Questions
Nal Pharmaceutical Group Limited's website is http://www.nalpharma.com
Nal Pharmaceutical Group Limited's LinkedIn profile is https://hk.linkedin.com/company/nalpharma
Nal Pharmaceutical Group Limited has
4 employees.
View email and phone details for 4
employees at Nal Pharmaceutical Group Limited.
Nal Pharmaceutical Group Limited's industry is
Pharmaceutical Manufacturing
Nal Pharmaceutical Group Limited's top competitors are
Bright Future Pharmaceutical Lab. Ltd.,
Cac Business Solutions, Llc,
John Doe,
Kenneth C. Zick Consulting (Dba Kcz Enterprises, Llc),
Veehoo Vape Uae,
Beacon Associates Llc,
Diplen-Denta Inc.,
Nt Pharma,
Medclin Consulting, Llc,
Nanotech Pharma Inc..
Nal Pharmaceutical Group Limited's categories are Pharmaceutical Manufacturing
Nal Pharmaceutical Group Limited's founding year is 2006
